Unehealth

1. Celgene Corporation $3,403,425 68 payments
2. Pfizer Inc. $1,683,912 117 payments
3. Janssen Research & Development, LLC $1,465,937 250 payments
4. Takeda Pharmaceuticals U.S.A., Inc. $1,465,152 107 payments
5. Bavarian Nordic A/S $1,430,289 69 payments
6. Incyte Corporation $1,135,669 78 payments
7. Eli Lilly and Company $1,070,033 27 payments
8. Novo Nordisk AS $929,501 2,380 payments
9. AstraZeneca Pharmaceuticals LP $879,613 32 payments
10. BeiGene, Ltd. $873,657 117 payments

1. A Single Arm, Open Label, Phase 2 Study of Ruxolitinib in Sclerotic Chronic Graft Versus Host Disease After Failure of Systemic Glucocorticoids $944,800 9 payments
2. A Phase 1/2 Open-Label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Tak-573 As A Single Agent in Patients With Refractory Multiple Myeloma $825,225 17 payments
3. Nct05238025 $799,698 25 payments
4. A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM) (JCAR017-BCM-003) $788,914 1 payment
5. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $647,890 50 payments
6. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $630,591 44 payments
7. A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $536,651 92 payments
8. A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $518,860 19 payments
9. A Phase I/II study to test the immunostimulatory effects of consolidative hypofractionated radiation therapy (hfRT) for boosting the residual primary lung cancer in combination with anti-PD-L1 immunotherapy after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC) $490,509 5 payments
10. Ex9536-4388 $456,921 586 payments

1. Overhead $253,577 6 payments
2. Patient care $62,840 3 payments
3. Non-patient care $62,123 9 payments
4. Other $27,773 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.